Reviewed by the Help Dementia Editorial Team — our editors review every article for accuracy against guidance from the National Institute on Aging, the Alzheimer’s Association, and peer-reviewed sources.
Market access sits at the center of this dementia and brain health question.
Market access strategy reports provide pharmaceutical manufacturers with critical roadmaps for successfully launching Alzheimer’s drugs in an increasingly complex healthcare landscape. These comprehensive guides analyze reimbursement requirements, payer negotiations, patient access barriers, and competitive positioning—helping drug developers navigate the unique challenges of bringing disease-modifying Alzheimer’s therapies to patients. With Leqembi approved in January 2023 and Kisunla following in July 2024, the approval phase is just the beginning; real-world access depends on masterful market strategy that addresses payer concerns, clinical evidence, and administrative burden.
The Alzheimer’s therapeutics market is projected to reach $13.13 billion by 2035, with expectations for $17 billion in revenue across 8 million patients by 2033. Yet despite these growth projections and breakthrough clinical data, market access remains the true bottleneck. Unlike oncology or cardiovascular drugs, disease-modifying Alzheimer’s treatments face skepticism from payers who question cost-effectiveness, worry about long-term safety in aging populations, and demand proof of real-world benefit. Market access strategy reports guide companies through these negotiations by providing data, economic models, and positioning frameworks that turn approvals into reimbursement and prescriptions.
Table of Contents
- Why Market Access Strategy Reports Matter More Than FDA Approval
- Reimbursement Architecture and the Coverage with Evidence Development Model
- Pricing Strategy and Cost Barriers to Patient Access
- Administration Burden as an Overlooked Market Access Barrier
- Global Variations and International Market Access Fragmentation
- Value-Based Contracting as Strategic Differentiation
- Future Outlook and Pipeline Considerations
- Conclusion
Why Market Access Strategy Reports Matter More Than FDA Approval
Many drug developers mistakenly believe FDA approval signals market success, but approval and access are fundamentally different challenges. A market access strategy report functions as a business plan for payer engagement, identifying which healthcare systems will cover the drug, under what conditions, and at what price. For Alzheimer’s drugs specifically, this means understanding Medicare’s “coverage with evidence development” requirements, navigating state Medicaid variations, and preparing for international health technology assessment rejections like the UK’s NICE ruling against Kisunla and Leqembi reimbursement.
The stakes are concrete. Leqembi carries a $26,500 annual price tag and requires biweekly infusions, while Kisunla costs $32,000 annually with dosing ranging from $12,522 for six months to $48,896 for 18 months depending on treatment duration. A comprehensive market access strategy identifies which patient segments are most likely to access therapy, which payers will prioritize coverage, and how to position the value proposition to overcome cost objections. Without this strategic groundwork, even approved drugs sit on pharmacy shelves underutilized—a cautionary tale from previous Alzheimer’s drug launches that failed to generate expected revenue despite FDA approval.
Reimbursement Architecture and the Coverage with Evidence Development Model
Medicare’s approach to Leqembi reimbursement through “coverage with evidence development” represents a watershed moment in how payers view Alzheimer’s drugs. Rather than blanket approval, Medicare requires patients to enroll in a registry while receiving the drug, effectively making the entire patient population subjects in a long-term evidence study. This arrangement protects payers from reimbursing ineffective therapy while theoretically protecting patients through continuous monitoring. However, the practical impact is significant: enrollment friction, data collection burden on healthcare providers, and uncertainty about what evidence might trigger coverage withdrawal create a chilling effect on uptake.
The UK’s NICE rejection of both Kisunla and Leqembi over cost-effectiveness concerns is the cautionary tale every manufacturer must internalize. NICE calculated that adding both drugs could cost the NHS £500 million to £1 billion annually—an unsustainable figure when applied to all eligible patients. This rejection occurred despite robust clinical trial data showing cognitive decline slowing, because payers use a different cost-benefit calculus than clinicians. A market access strategy report for European launches must address this head-on, providing health economic models that demonstrate value in the payer’s framework, not the researcher’s framework. The warning here is blunt: clinical efficacy does not guarantee reimbursement, and international access requires fundamentally different evidence packages.
Pricing Strategy and Cost Barriers to Patient Access
The announced prices for Leqembi ($26,500 annually) and Kisunla ($32,000 annually wholesale) reflect manufacturer decisions that immediately constrain patient access, particularly for uninsured and underinsured populations. These prices target Medicare and commercial insurance coverage, but even insured patients face substantial out-of-pocket costs depending on copay structures and plan design. Market access strategy reports must reconcile the tension between sustainable pricing that supports R&D investment and access pricing that reaches the 6 million Americans with Alzheimer’s disease. Real-world comparison: Leqembi now offers a subcutaneous maintenance formulation (LEQEMBI IQLIK), launched in October 2025, which reduces the IV administration burden that previously limited uptake.
This product iteration reflects how market access strategy extends beyond launch to addressing practical barriers identified post-approval. However, the subcutaneous option doesn’t address the core pricing barrier—it only solves the delivery inconvenience. Manufacturers using market access strategies are increasingly adopting value-based contracting tied to cognitive decline reduction outcomes, essentially offering performance guarantees that reassure payers their reimbursement is tied to measurable patient benefit. This approach acknowledges that payers no longer accept drug company assertions about value; they demand documented evidence in real-world populations.
Administration Burden as an Overlooked Market Access Barrier
The IV administration requirement for both Leqembi and Kisunla represents a substantial but underappreciated market access barrier. Patients with cognitive decline must arrange biweekly infusions, coordinate with infusion centers, and manage the logistics of recurring visits—burdens that disproportionately affect rural patients, those with limited transportation, and caregivers already stretched managing behavioral symptoms and cognitive decline. Market access strategy reports increasingly highlight this reality and use it as justification for expanded access programs or alternative delivery mechanisms.
The October 2025 launch of LEQEMBI IQLIK addressed this specific barrier by offering subcutaneous injection, a shift that emerged from market access research identifying administration burden as a primary reason eligible patients refused treatment. This example demonstrates how market access strategy guides post-approval product development. Manufacturers must decide: invest in easier administration formulations that expand access, or maintain existing routes and accept constrained uptake? The tradeoff is real—subcutaneous formulations require additional regulatory studies and manufacturing investment, but they unlock entire patient populations previously lost to IV burden.
Global Variations and International Market Access Fragmentation
Alzheimer’s drug market access is not monolithic across geographies—NICE’s rejection of both Leqembi and Kisunla in the UK stands in sharp contrast to FDA approval and Medicare coverage in the United States. This fragmentation means manufacturers must develop region-specific market access strategies that account for local payer frameworks, health system budgets, and competitive landscapes. The warning is direct: success in the US market does not translate automatically to Europe, Japan, or other developed markets.
Market access strategy reports for international launches must include health economic models tailored to each region’s cost-effectiveness thresholds. The UK NICE analysis showing £500 million to £1 billion annual costs for universal access sets a ceiling that constrains global expansion. Manufacturers pursuing European access must either demonstrate cost-effectiveness within those parameters (via improved clinical outcomes or reduced price) or target narrower patient populations where cost per patient is more defensible. This reality explains why Leqembi and Kisunla remain primarily available in the US—global market access for these therapies remains incomplete, and each additional country launch requires distinct market access strategy work.
Value-Based Contracting as Strategic Differentiation
Value-based contracting represents the next frontier in Alzheimer’s drug market access, moving beyond traditional price negotiation toward outcome-guaranteed agreements. Under these models, manufacturers agree that reimbursement is contingent on demonstrated cognitive benefit—if patients don’t show the expected decline reduction, payers pay discounted rates or receive rebates. This approach directly addresses payer skepticism by aligning financial incentives with clinical outcomes.
Market access strategy experts increasingly recommend value-based contracting specifically for disease-modifying Alzheimer’s drugs because the clinical endpoints (measured by cognitive scales like ADAS-cog) translate poorly to patient understanding and payer confidence. By anchoring reimbursement to measurable outcomes, manufacturers reassure payers while shifting some commercial risk from payer to manufacturer. The limitation: value-based contracting requires robust real-world data infrastructure, registry enrollment, and outcome measurement capability—infrastructure that must be built into launch strategy from the beginning, not retrofitted afterward.
Future Outlook and Pipeline Considerations
The Alzheimer’s therapeutics market is projected to grow from $10.09 billion in 2025 to $10.99 billion in 2026, representing 8.9% compound annual growth. This expansion reflects not only Leqembi and Kisunla uptake but also the pipeline of additional disease-modifying therapies in development. As more options arrive, market access becomes increasingly competitive—early entrants like Leqembi benefit from first-mover advantage and established payer relationships, while subsequent therapies must differentiate on cost, convenience, or superior efficacy.
Emerging market access strategies emphasize early health technology assessment engagement, meaning manufacturers discuss evidence packages with payers before pivotal trials conclude. This “parallel review” approach shortens the time between approval and reimbursement decision, a critical advantage when competitive products are launching. The forward-looking insight is that future Alzheimer’s drug launches will succeed or fail based on market access excellence, not just clinical trial success. Manufacturers investing now in registry infrastructure, health economic expertise, and payer relationships will dominate the $17 billion market projected for 2033.
Conclusion
Market access strategy reports are no longer optional add-ons to drug development—they are essential blueprints that determine whether FDA-approved Alzheimer’s therapies actually reach patients. These reports map reimbursement requirements, quantify payer concerns, identify access barriers like IV administration burden, and position value propositions that resonate with the economics-focused healthcare systems controlling access. The gap between FDA approval and real-world patient access, vividly illustrated by UK NICE rejections despite US Medicare coverage, underscores why strategic market navigation matters.
For patients and caregivers, this reality means understanding that approved medications may not be immediately accessible through their insurance or healthcare system. For manufacturers, it means embedding market access thinking into clinical development strategy from early stages. The Alzheimer’s therapeutics market opportunity is substantial—$17 billion by 2033 across millions of patients—but only for companies that master the intricate choreography of evidence generation, payer negotiation, and access strategy that transforms approvals into prescriptions and prescriptions into patient outcomes.
You Might Also Like
- Quarterly Earnings Reports Reflect Alzheimer’s Drug Revenue Trends
- Clinical Pharmacology Updates Guide Alzheimer’s Medication Dosing
- Regulatory Science Programs Train Experts in Alzheimer’s Drug Evaluation
For more, see Alzheimer’s Association.
